Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $3.7B | $631M | $314M | $465M | 39.8% | 65.2% | -212.8% |
| 2024 | $2.2B | $-179M | $-278M | $-43M | -414.6% | 23.0% | -36.8% |
| 2023 | $1.8B | $-258M | $-440M | $42M | 199.5% | 76.2% | -61.1% |
| 2022 | $1.0B | $-927M | $-1.1B | $-613M | 714.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,037.42 | 1,828.29 | 2,248.24 | 3,713.94 |
| Operating Revenue | - | 1,037.42 | 1,828.29 | 2,248.24 | 3,713.94 |
| Cost Of Revenue | - | 168.82 | 310.41 | 323.37 | 681.87 |
| Gross Profit | - | 868.60 | 1,517.89 | 1,924.87 | 3,032.07 |
| Operating Expense | - | 1,653.67 | 1,800.06 | 2,101.76 | 2,530.49 |
| Research And Development | - | 883.02 | 1,004.42 | 1,126.23 | 1,319.78 |
| Selling General And Administration | - | 770.66 | 795.65 | 975.53 | 1,210.71 |
| Total Expenses | - | 1,822.49 | 2,110.47 | 2,425.13 | 3,212.36 |
| Operating Income | - | -785.07 | -282.18 | -176.88 | 501.58 |
| Total Operating Income As Reported | - | -785.07 | -282.18 | -176.88 | 501.58 |
| EBITDA | - | -926.56 | -258.24 | -178.85 | 631.44 |
| Normalized EBITDA | - | -722 | -150.30 | -5.06 | 676.22 |
| EBIT | - | -971.02 | -312.30 | -235.52 | 575.78 |
| Interest Income | - | 24.81 | 95.56 | 121.99 | 111.47 |
| Interest Expense | - | 155.97 | 121.22 | 141.86 | 252.63 |
| Net Interest Income | - | -131.16 | -25.66 | -19.87 | -141.16 |
| Other Non Operating Income Expenses | - | -6.20 | -17.74 | -6.83 | 7.51 |
| Other Income Expense | - | -210.76 | -125.68 | -180.62 | -37.27 |
| Interest Income Non Operating | - | 24.81 | 95.56 | 121.99 | 111.47 |
| Interest Expense Non Operating | - | 155.97 | 121.22 | 141.86 | 252.63 |
| Net Non Operating Interest Income Expense | - | -131.16 | -25.66 | -19.87 | -141.16 |
| Pretax Income | - | -1,126.99 | -433.52 | -377.38 | 323.15 |
| Tax Provision | - | 4.16 | 6.72 | -99.22 | 9.40 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -42.96 | -22.67 | -45.71 | -1.30 |
| Net Income Continuous Operations | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Net Income From Continuing And Discontinued Operation | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Net Income From Continuing Operation Net Minority Interest | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Net Income | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Net Income Common Stockholders | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Net Income Including Noncontrolling Interests | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Normalized Income | - | -969.56 | -354.97 | -150.07 | 357.23 |
| Diluted NI Availto Com Stockholders | - | -1,131.16 | -440.24 | -278.16 | 313.75 |
| Basic Average Shares | - | 121.69 | 124.91 | 127.65 | 131 |
| Diluted Average Shares | - | 121.69 | 124.91 | 127.65 | 134.68 |
| Reconciled Depreciation | - | 44.47 | 54.05 | 56.67 | 55.66 |
| Reconciled Cost Of Revenue | - | 168.82 | 310.41 | 323.37 | 681.87 |
| Total Unusual Items | - | -204.56 | -107.94 | -173.79 | -44.78 |
| Total Unusual Items Excluding Goodwill | - | -204.56 | -107.94 | -173.79 | -44.78 |
| Special Income Charges | - | -76.59 | 0 | 0 | -42.47 |
| Other Special Charges | - | 76.59 | - | - | 42.47 |
| Gain On Sale Of Security | - | -127.97 | -107.94 | -173.79 | -2.31 |
| General And Administrative Expense | - | 770.66 | 795.65 | 975.53 | 1,210.71 |
| Other Gand A | - | 226.94 | 226.66 | 274.54 | 348.98 |
| Salaries And Wages | - | 411.75 | 423.30 | 531.08 | 668.30 |
| Rent Expense Supplemental | - | 131.97 | 145.69 | 169.91 | 193.44 |
| Rent And Landing Fees | - | 131.97 | 145.69 | 169.91 | 193.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc.this co. | ALNY | $40.5B | 129.21↑ premium | 51.37 | 39.8% | 61.62 |
| Cardinal Health, Inc. | CAH | $47.2B | 30.27 | -16.99 | -56.1% | 16.71 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 | 27.75 | 66.0% | 30.06 |
| Humana Inc. | HUM | $42.0B | 35.35 | 2.38 | 6.7% | - |
| Becton, Dickinson and Company | BDX |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $41.2B |
| 24.56 |
| 1.62 |
| 6.6% |
| 12.06 |
| Agilent Technologies, Inc. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| Waters Corporation | WAT | $37.0B | 57.52 | 14.43 | 25.1% | 36.74 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Peer Median | - | 30.13 | 5.30 | 20.1% | 16.71 | |
Historically, Jun has averaged the highest return (+18.1%); Jan the lowest (-6.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.0%Negative MonthJan 2026: -14.99% | -1.5%Neutral MonthFeb 2026: -1.52% | -0.6%Neutral MonthMar 2026: -0.62% | -6.5%Negative MonthApr 2026: -6.46% | -2.4%Negative MonthMay 2026: -2.43% | -0.3%Neutral MonthJun 2026: -0.31% | -31.7%Negative MonthJul 2026: -31.73% | +18.0%*Positive MonthAug 2026: +18.05% | — | — | — | — |
| 2025 | +15.3%Positive MonthJan 2025: +15.30% | -9.1%Negative MonthFeb 2025: -9.05% | +9.4%Positive MonthMar 2025: +9.43% | -2.5%Negative MonthApr 2025: -2.51% | +15.7%Positive MonthMay 2025: +15.70% | +7.1%Positive MonthJun 2025: +7.07% | +20.3%Positive MonthJul 2025: +20.29% | +13.8%Positive MonthAug 2025: +13.84% | +2.1%Positive MonthSep 2025: +2.13% | +0.0%Neutral MonthOct 2025: +0.01% | -1.1%Neutral MonthNov 2025: -1.05% | -11.9%Negative MonthDec 2025: -11.87% |
| 2024 | -9.7%Negative MonthJan 2024: -9.67% | -12.6%Negative MonthFeb 2024: -12.62% | -1.1%Neutral MonthMar 2024: -1.09% | -3.7%Negative MonthApr 2024: -3.68% | +3.1%Positive MonthMay 2024: +3.11% | +63.7%Positive MonthJun 2024: +63.71% | -2.3%Negative MonthJul 2024: -2.28% | +10.6%Positive MonthAug 2024: +10.62% | +4.7%Positive MonthSep 2024: +4.70% | -3.1%Negative MonthOct 2024: -3.07% | -5.1%Negative MonthNov 2024: -5.07% | -7.0%Negative MonthDec 2024: -7.02% |
| 2023 | -4.7%Negative MonthJan 2023: -4.73% | -15.4%Negative MonthFeb 2023: -15.44% | +4.6%Positive MonthMar 2023: +4.63% | -0.6%Neutral MonthApr 2023: -0.56% | -7.1%Negative MonthMay 2023: -7.12% | +2.7%Positive MonthJun 2023: +2.66% | +2.9%Positive MonthJul 2023: +2.87% | +1.2%Neutral MonthAug 2023: +1.24% | -10.5%Negative MonthSep 2023: -10.47% | -14.3%Negative MonthOct 2023: -14.29% | +10.8%Positive MonthNov 2023: +10.84% | +13.8%Positive MonthDec 2023: +13.77% |
| 2022 | -18.9%Negative MonthJan 2022: -18.86% | +14.7%Positive MonthFeb 2022: +14.72% | +3.4%Positive MonthMar 2022: +3.45% | -18.3%Negative MonthApr 2022: -18.29% | -5.7%Negative MonthMay 2022: -5.72% | +15.9%Positive MonthJun 2022: +15.94% | -2.6%Negative MonthJul 2022: -2.61% | +45.5%Positive MonthAug 2022: +45.50% | -3.1%Negative MonthSep 2022: -3.15% | +3.5%Positive MonthOct 2022: +3.55% | +6.4%Positive MonthNov 2022: +6.43% | +7.7%Positive MonthDec 2022: +7.73% |
| 2021 | — | — | — | — | +1.0%Neutral MonthMay 2021: +0.96% | +19.4%Positive MonthJun 2021: +19.39% | +5.6%Positive MonthJul 2021: +5.56% | +12.6%Positive MonthAug 2021: +12.57% | -6.3%Negative MonthSep 2021: -6.27% | -15.5%Negative MonthOct 2021: -15.49% | +15.2%Positive MonthNov 2021: +15.19% | -7.7%Negative MonthDec 2021: -7.74% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
